Glaucoma News

Older drivers with glaucoma are involved in automobile accidents at a higher rate than their similarly aged counterparts without glaucoma, according to a study.

Poor sleep parameters, including sleep duration, latency and daytime dysfunction, are associated with glaucoma, either as a risk factor or as a consequence, according to a study.

Alembic Pharmaceuticals’ abbreviated new drug application for dorzolamide hydrochloride ophthalmic solution USP 2% has been approved by the FDA, according to a press release.

Risk assessment and risk management are common tools in modern society. Although the concept can be traced back to the ancient Greeks from around 400 BC, the science of risk management is a product of the late 20th century, according to Aven.

July’s glaucoma news included updates on trial enrollments and study results.

No additional benefit in IOP-lowering effect was seen when goniosynechialysis was added to phacoemulsification in patients with primary angle closure glaucoma and cataract.

MicroSurgical Technology and Ike Ahmed, MD, have developed the MST 19-gauge Ahmed micro stent cutter, according to a press release.

Patient enrollment in a phase 1 clinical trial of PolyActiva’s biodegradable, slow-release ocular implant for the treatment of glaucoma has been completed, the company announced in a press release.

Here are some of the past week’s top stories:

Patients with higher levels of cholesterol are more at risk for primary open-angle glaucoma, while those who take statins to control cholesterol levels are at less risk, according to a study.